Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

118.13 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
40 41 Next >
Abbott Laboratories Clocks Strong Q2 Growth In Underlying Base Business, Reaffirms FY23 Outlook
Abbott Laboratories (NYSE: ABT) has reported Q2 FY23 adjusted EPS of $1.08, down 25% Y/Y, beating the consensus of $1.05. 
Via Benzinga
Abbott Stock Edges Higher As Earnings Decline But Still Top Forecasts
The company continues to expect some Covid sales this year, but cut its outlook. 
Via Investor's Business Daily
Earnings Scheduled For July 20, 2023
Companies Reporting Before The Bell • Taiwan Semiconductor (NYSE:TSM) is estimated to report quarterly earnings at $1.08 per share on revenue of $15.49 billion. 
Via Benzinga
Abbott Laboratories's Earnings Outlook
Via Benzinga
What's In Store For Abbott Laboratories In Q2 Earnings?
Abbott Laboratories is slated to report second-quarter 2023 results on July 20 before the market opens. 
Via Talk Markets
Johnson & Johnson, Tesla And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Markets Remain Bullish After Dow Rises For Eighth Consecutive Session
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Wednesday. The Dow Jones gained recorded gains for the eighth straight session on Wednesday, its longest winning streak since... 
Via Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Abbott Scores FDA Nod For First Dual-Chamber Leadless Pacemaker To Treat Abnormal, Slow Heart Rhythms
The FDA has approved Abbott Laboratories' (NYSE: ABT) AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system to treat  
Via Benzinga
(ABT) - Analyzing Abbott Laboratories's Short Interest
Via Benzinga
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
GE HealthCare's Solid Demand And Sensible Margin Targets: Morgan Stanley Sees Potential Upside Despite Street's High Expectations
Morgan Stanley analyst Patrick Wood initiated coverage on GE HealthCare Technologies Inc (NASDAQ: GEHC) with an Equal-Weight rating and a  
Via Benzinga
Dexcom, A Top 2% Stock, Raises 2025 Outlook Amid 'Rapidly' Expanding Diabetes Market
The company makes continuous glucose monitors for patients with diabetes. 
Via Investor's Business Daily
Agilent Technologies Stock: Ready to Rise off the Floor
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider. 
Via MarketBeat
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next. 
Via MarketBeat
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval
The FDA has approved Surmodics Inc's (NASDAQ: SRDX) SurVeil drug-coated balloon (DCB), a next-generation device  
Via Benzinga
3 Passive Income Stocks to Hold for the Next 20 Years
These three stocks are likely to keep increasing their dividends over years or even decades. 
Via The Motley Fool
Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application
In an investor presentation, Surmodics Inc (NASDAQ: SRDX) said it submitte 
Via Benzinga
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Recent troubles won't stop these companies' long-term trajectories. 
Via The Motley Fool
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning 
Via MarketBeat
Exposures COVID-19 Product Safety
Nvidia Chief Flags Dangers To US Chips Act, Disney, Shell, Gucci Allegedly Used Worthless Carbon Credits, Microsoft's Daring Attempt to Outshine Google In Search Game: Today's Top Stories
Benzinga 
Via Benzinga
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
Via Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy
U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Abbott Laboratories (NYSE: ABT) Similac and other formulas that they said had... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.